ArticleFrontiers in neurology
Serum neurofilament light chain and disease-modifying treatment as predictors of cognitive decline in multiple sclerosis.
Article in Frontiers in neurology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cognitive impairment (CI) is a prevalent and early problem in multiple sclerosis (MS). Its detection and monitoring might help prevent cognitive decline and potentially inform treatment decisions. Objective: The aim of this study was to analyze the possible associations of cognitive decline and neurofilament levels, disability measures, and disease-modifying treatments (DMTs) in patients with MS (PwMS). Methods: 64 PwMS and 14 healthy controls participated in this prospective study. Neurofilament light chain (NfL) levels were measured in the cerebrospinal fluid (CSF) samples of PwMS and serum samples of both groups. Serum samples, cognitive testing using Brief International Cognitive Assessment for MS (BICAMS) battery and disability assessment using EDSS, Nine-Hole Peg Test (9HPT) and Timed 25-Foot Walk Test (T25FWT) were evaluated at the time of diagnosis and at follow-up at 12 months. Longitudinal change in BICAMS subtest scores was calculated and its associations with NfL concentration, disability measures and demographic/clinical data were analyzed. Results: All PwMS were diagnosed with relapsing MS and 78.1% were started on platform DMTs, while the rest were prescribed higher-efficacy DMTs. PwMS had significantly higher sNfL concentration at baseline (11.95 vs. 5.40 pg./mL, Conclusion: Our findings highlight the potential of serum NfL as a marker of early IPS decline. Treatment with higher-efficacy DMTs early after diagnosis may be protective against early cognitive decline in MS.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.